17,261 trials
Melanoma · Carcinoma, Hepatocellular · Colorectal Neoplasms
Primary: Phase 1b Part: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Actinic Keratosis
Primary: Treatment Efficacy Based on Participant AK Lesion Clearance — 59; 34; 43; 76 percentage of AK lesions
Relapsing Multiple Sclerosis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 17; 17; 24; 20 Participants
Hypertension
Primary: Categorical Classification of Subjects Into Responders vs. Non-responders — 10; 2; 4; 19 Participants
Acute Coronary Syndrome
Primary: Change in LDL-Cholesterol — -70.59; -44.78 percent change mg/dL — p=.0001
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months
B-Cell Non-Hodgkin Lymphoma
Primary: Absence of Any Grade Cytokine Release Syndrome (CRS) — 16; 9 Participants
Pompe Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events (AEs) Leading to Discontinuation of Study…
SARS-CoV-2 · COVID-19
Primary: Part A: Geometric Mean Titer (GMT) of Serum Neutralization Titers Against Pseudovirus Bearing SARS-CoV-2 Strain XX Spike Protein — 1266.7; 1786.9; 2122.1; 2218.6 Titers
Post-Traumatic Headache
Primary: Change in the Number of Days Experiencing Moderate-to-Severe Headaches — -8; -0.33 Days
Temporomandibular Dysfunction
Primary: Characteristic Facial Pain Score — 6.52; 6.55; 5.11; 5.47 units on a scale — p=0.020
Myelodysplastic Syndromes · Secondary Acute Myeloid Leukemia
Primary: Maximum Tolerated Dose of CD8 Depleted Non-engrafting HLA-mismatched Unrelated Donor Lymphocytes Infusion (NE-DLI) — 5 10^7 CD4 cells/kg
Congenital Adrenal Hyperplasia · CAH - Congenital Adrenal Hyperplasia
Primary: Safety of SPR001 in Patients With CAH — 6; 5; 4 Participants
HIV-1-infection
Primary: Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core) — 0; 0; 0; 0 Participants
Prader-Willi Syndrome
Primary: Excessive Daytime Sleepiness — -3.5; -5.0; -3.9 score on a scale